Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2013 Results
Date:5/9/2013

gement team as Senior Vice President, Chief Medical Officer.  He had assumed the role of Vanda's acting Chief Medical Officer in October 2012.  Dr. Baroldi previously served as Vanda's Senior Vice President and Chief Medical Officer from July 2006 through January 2009.
He has also served in senior clinical development positions at Galileo Research, Supernus Pharmaceuticals, Chiesi Famaceutici SpA, and Novartis.

2013 FINANCIAL GUIDANCE2013 financial guidance assumes a mid-year NDA submission for tasimelteon for Non-24 is accepted by the FDA for Standard Review.  2013 expenses are expected to reflect lower research and development spending as compared to 2012 and an increase in commercial spending that is commensurate to progress with the tasimelteon NDA filing.

  • Full year 2013 decrease in Cash is expected to be between $45.0 and $50.0 million, compared to $47.5 million for 2012.
  • Total 2013 operating expenses are expected to be between $57.0 and $62.0 million.  This includes Fanapt® intangible asset amortization of $1.5 million and $4.0 to $6.0 million of non-cash stock based compensation.
    Total 2012 operating expenses were $61.0 million.
  • 2013 operating expense guidance assumes $4.3 million in milestone payments due upon the acceptance by the FDA of a tasimelteon NDA submission and $3.0 to $4.0 million in NDA filing-related expenses.
  • CONFERENCE CALLVanda has scheduled a conference call for today, Thursday, May 9, 2013, at 10:00 AM ET.  During the call, Vanda's management will discuss the first quarter 2013 financial results and other corporate activities.  Investors can call 1-877-280-4962 (domestic) and 1-857-244-7319 (international) and use passcode 32610810.  A replay of the call will be available beginning Thursday, May 9, 2013 at 12:00 PM ET and will be accessible until Thursday, May 16, 2013, at 5:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic call
    '/>"/>

    SOURCE Vanda Pharmaceuticals Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
    3. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
    4. Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
    5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
    6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    10. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    11. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 2014 The global companion diagnostics ... 2019. It is expected to grow at a ... was valued at $1.8 billion in 2013, according ... Research. , For more information regarding analysis details ... The research report, titled “Companion Diagnostics Market (Breast ...
    (Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
    (Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
    (Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
    Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
    ... Corporation,s (Amex: ETC ) ("ETC" or the ... contract with the Netherlands,Institute for Safety, NIFV, to ... Simulator for Aircraft Rescue Fire Fighting., The ... military helicopter,scenario consisting of AH-64 Apache helicopters parked ...
    ... FRANCISCO, Calif., Nov. 3 Portola,Pharmaceuticals, a ... advances in cardiovascular and inflammatory,diseases, and cancer, ... enrollment,in a large Phase II clinical trial ... inhibitor anticoagulant, for stroke prevention in patients ...
    ... Therapeutics, Inc.,(Nasdaq: HALO ), a biopharmaceutical ... matrix, today announced it has started,a Phase ... enzyme,(rHuPH20) co-formulations with Humulin(R) R (regular insulin ... Type 1 diabetic,patients. This study is designed ...
    Cached Biology Technology:Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 2Environmental Tectonics Corporation's Simulation Division Receives New ADMS Contract from Netherlands Institute for Safety 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 2Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 3Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation 4Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 2Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 3Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients 4
    (Date:8/29/2014)... stretch them, twist them, fold them: modern materials that ... potential, whether as artificial skin or electronic paper. , ... a challenge but a new way of working with ... a game-changer. , Previous success in the field ... use of precious gold and silver nanowires. , ...
    (Date:8/28/2014)... pleased to announce the selection of Dr. Fred Baxendale ... acknowledges those who have served ESA for at least ... the Society that has reached an extraordinary level. Candidates ... Board and then voted on by the ESA membership. ... at Entomology 2014, ESA,s Annual Meeting in Portland, Oregon ...
    (Date:8/28/2014)... news release is available in German . ... water fish, owes its name to a striking pattern of ... types, black cells, reflective silvery cells, and yellow cells emerge ... and arrange as a multilayered mosaic to compose the characteristic ... three cell types have to interact to form proper stripes, ...
    Breaking Biology News(10 mins):Copper shines as flexible conductor 2Fred Baxendale selected as Honorary Member of the Entomological Society of America 2How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
    ... in German . , Researchers at the Max ... the Czech Academy of Sciences in Prague have developed a new ... acids, amino acids and other organic substances from plant or animal ... liter -- is sufficient to identify certain blood related metabolites. ...
    ... of fishing gear could help the world,s coral reefs and their ... team of scientists led by Dr Josh Cinner of the ARC ... has proposed that bans on fishing gear - like spear guns, ... in the recovery of reefs and fish populations hard hit by ...
    ... Although worlds apart, the way fish learn could be ... a new research study. A common species of fish ... nine-spined stickleback, could be the first animal shown to exhibit ... compare the behaviour of other sticklebacks with their own experience ...
    Cached Biology News:An easy way to find a needle in a haystack by removing the haystack 2An easy way to find a needle in a haystack by removing the haystack 3Gear bans 'can help save reefs' 2Gear bans 'can help save reefs' 3Common fish species has 'human' ability to learn 2Common fish species has 'human' ability to learn 3
    Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
    Request Info...
    MOUSE ANTI HUMAN FACTOR I...
    albumin from bovine serum (BSA), tetramethylrhodamine conjugate...
    Biology Products: